'In silico' oncology for clinical decision making in the context of nephroblastoma

Graf, N; Hoppe, A; Georgiadi, E; Belleman, R; Desmedt, C; Dionysiou, D; Erdt, M; Jacques, J; Kolokotroni, E; Lunzer, A; Tsiknakis, M; Stamatakos, G

dc.contributor.author	Graf, N	en
dc.contributor.author	Hoppe, A	en
dc.contributor.author	Georgiadi, E	en
dc.contributor.author	Belleman, R	en
dc.contributor.author	Desmedt, C	en
dc.contributor.author	Dionysiou, D	en
dc.contributor.author	Erdt, M	en
dc.contributor.author	Jacques, J	en
dc.contributor.author	Kolokotroni, E	en
dc.contributor.author	Lunzer, A	en
dc.contributor.author	Tsiknakis, M	en
dc.contributor.author	Stamatakos, G	en
dc.date.accessioned	2014-03-01T11:44:48Z
dc.date.available	2014-03-01T11:44:48Z
dc.date.issued	2009	en
dc.identifier.issn	0300-8630	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/37183
dc.subject	Decision making	en
dc.subject	In silico oncology	en
dc.subject	Nephroblastoma	en
dc.subject	Oncosimulator	en
dc.subject.classification	Pediatrics	en
dc.subject.other	dactinomycin	en
dc.subject.other	vincristine	en
dc.subject.other	antineoplastic agent	en
dc.subject.other	cancer combination chemotherapy	en
dc.subject.other	cancer model	en
dc.subject.other	cancer therapy	en
dc.subject.other	clinical decision making	en
dc.subject.other	computer model	en
dc.subject.other	computer program	en
dc.subject.other	computer simulation	en
dc.subject.other	differential diagnosis	en
dc.subject.other	digital imaging and communications in medicine	en
dc.subject.other	human	en
dc.subject.other	in vivo study	en
dc.subject.other	nephroblastoma	en
dc.subject.other	nuclear magnetic resonance imaging	en
dc.subject.other	oncology	en
dc.subject.other	prediction	en
dc.subject.other	preoperative evaluation	en
dc.subject.other	reliability	en
dc.subject.other	review	en
dc.subject.other	three dimensional imaging	en
dc.subject.other	treatment outcome	en
dc.subject.other	tumor volume	en
dc.subject.other	validation process	en
dc.subject.other	adjuvant therapy	en
dc.subject.other	algorithm	en
dc.subject.other	child	en
dc.subject.other	decision support system	en
dc.subject.other	game	en
dc.subject.other	kidney	en
dc.subject.other	kidney tumor	en
dc.subject.other	pathology	en
dc.subject.other	theoretical model	en
dc.subject.other	Algorithms	en
dc.subject.other	Antineoplastic Combined Chemotherapy Protocols	en
dc.subject.other	Child	en
dc.subject.other	Computer Simulation	en
dc.subject.other	Decision Support Techniques	en
dc.subject.other	Game Theory	en
dc.subject.other	Humans	en
dc.subject.other	Imaging, Three-Dimensional	en
dc.subject.other	Kidney	en
dc.subject.other	Kidney Neoplasms	en
dc.subject.other	Models, Theoretical	en
dc.subject.other	Neoadjuvant Therapy	en
dc.subject.other	Software	en
dc.subject.other	Treatment Outcome	en
dc.subject.other	Tumor Burden	en
dc.subject.other	Wilms Tumor	en
dc.title	'In silico' oncology for clinical decision making in the context of nephroblastoma	en
heal.type	other	en
heal.identifier.primary	10.1055/s-0029-1216368	en
heal.identifier.secondary	http://dx.doi.org/10.1055/s-0029-1216368	en
heal.language	English	en
heal.publicationDate	2009	en
heal.abstract	The present paper outlines the initial version of the ACGT (Advancing Clinico-Genomic Trials) an Integrated Project, partly funded by the EC (FP6-2005-IST-026996)I-Oncosimulator as an integrated software system simulating in vivo tumour response to therapeutic modalities within the clinical trials environment aiming to support clinical decision making in individual patients. Cancer treatment optimization is the main goal of the system. The document refers to the technology of the system and the clinical requirements and the types of medical data needed for exploitation in the case of nephroblastoma. The outcome of an initial step towards the clinical adaptation and validation of the system is presented and discussed. Use of anonymized real data before and after chemotherapeutic treatment for the case of the SIOP 2001/GPOH nephroblastoma clinical trial constitutes the basis of the clinical adaptation and validation process. By using real medical data concerning nephroblastoma for a single patient in conjunction with plausible values for the model parameters (based on available literature) a reasonable prediction of the actual tumour volume shrinkage has been made possible. Obviously as more and more sets of medical data are exploited the reliability of the model tuning is expected to increase. The successful performance of the initial combined ACGT Oncosimulator platform, although usable up to now only as a test of principle, has been a particularly encouraging step towards the clinical translation of the system, being the first of its kind worldwide. © Georg Thieme Verlag KG Stuttgart New York.	en
heal.publisher	GEORG THIEME VERLAG KG	en
heal.journalName	Klinische Padiatrie	en
dc.identifier.doi	10.1055/s-0029-1216368	en
dc.identifier.isi	ISI:000266161300004	en
dc.identifier.volume	221	en
dc.identifier.issue	3	en
dc.identifier.spage	141	en
dc.identifier.epage	149	en